Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CDC25B | P30305 | 2/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CDC25A | P30304 | 1/20 | 0.44 |
| ▸ | CDC25C | P30307 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6719502 | 0.85 | CTNNB1 (0.59) | KMT2ACTNNB1ALDH1A1HPGDCDC25B | |
| SCHEMBL6176215 | 0.84 | KMT2A (0.51) | KMT2ACTNNB1ALDH1A1HPGDCDC25B | |
| SCHEMBL7262986 | 0.82 | KMT2A (0.50) | KMT2ACTNNB1ALDH1A1HPGDCDC25B | |
| SCHEMBL3936305 | 0.82 | KMT2A (0.50) | KMT2ACTNNB1ALDH1A1HPGDCDC25B | |
| SCHEMBL7905202 | 0.82 | KMT2A (0.50) | KMT2ACTNNB1ALDH1A1HPGDCDC25B | |
| SCHEMBL8465002 | 0.82 | KMT2A (0.50) | KMT2ACTNNB1ALDH1A1HPGDCDC25B | |
| SCHEMBL10389809 | 0.82 | CTNNB1 (0.52) | KMT2ACTNNB1ALDH1A1HPGDCDC25B | |
| SCHEMBL7322093 | 0.82 | CTNNB1 (0.60) | KMT2ACTNNB1ALDH1A1HPGDCDC25B | |
| SCHEMBL13821887 | 0.82 | EPHX2 (0.51) | KMT2ACTNNB1ALDH1A1HPGDCDC25B | |
| SCHEMBL6589138 | 0.81 | CTNNB1 (0.55) | KMT2ACTNNB1ALDH1A1HPGDCDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| US-6891005-B2 | Bridged metal complexes for gas phase polymerizations | BP CHEMICALS LIMITED (GB) | 2005-05-10 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030199650-A1 | Bridged metal complexes for gas phase polymerizations | BP CHEMICALS LIMITED | 2003-10-23 | — | — | US | disclosed |
| EP-1119575-B1 | BRIDGED METAL COMPLEXES | DOW CHEMICAL CO (US) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-1141034-B1 | BRIDGED METAL COMPLEXES FOR GAS PHASE POLYMERIZATIONS | BP CHEM INT LTD (GB) | 2002-10-30 | — | — | EP | disclosed |
| US-6376406-B1 | COORDINATION POLYMERIZATION CATALYSTS FOR ALPHA-OLEFINS | THE DOW CHEMICAL COMPANY | 2002-04-23 | — | — | US | disclosed |
| EP-1141034-A2 | BRIDGED METAL COMPLEXES FOR GAS PHASE POLYMERIZATIONS | BP Chemicals Limited (GB) | 2001-10-10 | — | — | EP | disclosed |
| US-6284905-B1 | GROUP 4 TRANSITION METAL COMPLEX CONTAINING A BORON OR ALUMINUM BRIDGING GROUP CONTAINING A NITROGEN CONTAINING ELECTRON DONATING GROUP, ESPECIALLY AN AMIDO GROUP; OLEFIN SOLUTION OR SLURRY POLYMERIZATION CATALYSTS | THE DOW CHEMICAL COMPANY | 2001-09-04 | — | — | US | disclosed |
| CN-1054598-C | Pharmacologically active hydrazine derivatives and processes for preparation thereof | NORVATIS CO (CH) | 2000-07-19 | — | — | CN | disclosed |
| WO-2000020462-A2 | BRIDGED METAL COMPLEXES FOR GAS PHASE POLYMERIZATIONS | BP CHEMICALS LIMITED (GB) | 2000-04-13 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| CN-1068333-A | Has hydrazine analog derivative of pharmacologically active and preparation method thereof | CIBA GEIGY AG (CH) | 1993-01-27 | — | — | CN | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | KMT2A 3442/4885CTNNB1 1728/4885ALDH1A1 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.